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Introduction
Restless legs syndrome (RLS) is a neurologic sleep and
movement disorder characterized by an irresistible
urge to move, with unpleasant limb sensations occur-
ring at rest and during the evening or night. It is one of
the leading causes of insomnia and possibly the com-
monest movement disorder known, but remains under-
recognized and undertreated. RLS affects 5–15% of the
general population, with a female preponderance of
almost 2:11. It may start at any age, but there is a
demonstrated increase in RLS among the elderly, with
an estimated prevalence of 10–35% among those older
than 65 years2. RLS symptoms may lead to anxiety, de-
pression, insomnia, and excessive daytime somnolence
that sometimes requires lifelong treatment. The severity
of RLS symptoms in older adults affects not only sleep
quality but also many aspects of quality of life, includ-
ing social functioning, daily functioning, and emotional
well-being3. In a 20-year follow-up study of Swedish
women, RLS resulting in excessive daytime sleepiness
was associated with increased mortality risk4. There-
fore, accurate diagnosis and therapy of the disorders
may substantially improve the quality of sleep and life
in this patient population. We summarize the recent
knowledge on diagnosis, epidemiology and treatment
of RLS, especially among elderly adults.
Diagnosis of RLS
The diagnosis of RLS is based on the history of the
patient, with input from the patient’s sleeping partner.
In 2003, the National Institutes of Health consensually
agreed to define RLS by four cardinal features5: (1) an
urge to move the limbs with or without sensation, (2) a
worsening urge to move at rest, (3) an improvement
with activity, and (4) a worsening urge to move in the
evening or nighttime.
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Restless legs syndrome is a sleep and movement disorder that affects 5–15% of the general population, with an
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One study showed that it was possible to screen for
RLS with good sensitivity and specificity by asking one
single question, “When you try to relax in the evening
or sleep at night, do you ever have unpleasant, restless
feelings in your legs that can be relieved by walking or
movement6?” An interview with a trained physician is
necessary for the correct diagnosis of RLS. If only ques-
tionnaires with the RLS criteria are given to patients,
this results in approximately 10–25% false positives due
to RLS mimicry7. The ability to verbally express experi-
enced limb sensations may be diminished in the elderly
by the impact of comorbid conditions, such as cognitive
impairment, speech disorders or aphasic syndromes.
Allen and colleagues5, therefore, developed new criteria
for the diagnosis of RLS among cognitively impaired
elderly adults (Table). Observation of the restless leg
movement behavior is helpful for the diagnosis. For
example, rubbing the legs or excessive motor activity at
night could indicate that the patient experiences sen-
sations and the urge to move. A detailed history of
restless leg movement given by family members and
caregivers is considered very important for diagnosing
RLS among these patients.
Several RLS rating scales were used to assess severity
in medical studies. The International RLS Study Group
rating scale, validated in 2003, is currently considered
the standard scale by most RLS specialists. The scale is
used to quantify the degree of RLS and monitor the pa-
tient longitudinally. This measure comprises 10 ques-
tions, each rated on a scale of 0–4, with a maximum
disability score of 40.
Prevalence of RLS
In the Restless Legs Syndrome Prevalence and Impact
Study8, 7.2% of the general population reported RLS
symptoms, but symptoms were moderately or severely
distressing in only 2.7%. The prevalence of RLS symp-
toms increased at least until the seventh or eighth
decade of life. The increasing prevalence of RLS with
age is partially due to the fact that, although RLS can
develop at any age, it rarely resolves on its own. The
prevalence may be lower in Asian populations than
that reported in Caucasian populations. In a recently
published Japanese population study of RLS9, the
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Table. Diagnostic criteria for the diagnosis of probable restless legs syndrome in the cognitively impaired elderly (all five are
necessary for diagnosis)
Essential criteria
1. Signs of leg discomfort, such as rubbing or kneading the legs and groaning while holding the lower extremities
2. Excessive motor activity in the lower extremities, such as pacing, fidgeting, repetitive kicking, tossing and turning in
bed, slapping the legs on the mattress, cycling movements of the lower limbs, repetitive foot tapping, rubbing the feet
together, and the inability to remain seated
3. Signs of leg discomfort are exclusively present or worsen during periods of rest or inactivity
4. Signs of leg discomfort are diminished with activity
5. Criteria 1 and 2 occur only in the evening or at night, or are worse at those times than during the day
Supportive criteria
1. Dopaminergic responsiveness
2. Patient’s past history as reported by a family member, caregiver or friend is suggestive of restless legs syndrome
3. A first degree, biologic relative (sibling, child or parent) has restless legs syndrome
4. Observed periodic limb movements while awake or during sleep
5. Periodic limb movements of sleep recorded by polysomnography or actigraphy
6. Significant sleep-onset problems
7. Better quality sleep in the day than at night
8. The use of restraints at night (for institutionalized patients)
9. Low serum ferritin level
10. End-stage renal disease
11. Diabetes
12. Clinical, electromyographic or nerve-conduction evidence of peripheral neuropathy or radiculopathy
Modified from Allen et al.5 with permission.
prevalence among inhabitants of Ajimu aged >65 years
was 0.96%. The distribution of age at onset in a large
cohort study showed that early- and late-onset RLS could
be separated with a cut-off at 36 years of age, clearly
differentiating patients with a primary RLS (early onset)
from those with secondary RLS10.
Comorbidity and Secondary Forms of RLS
Among the elderly population, RLS is associated with
other diseases such as iron deficiency, renal failure, dia-
betes mellitus, peripheral neuropathy, and various other
conditions such as rheumatoid arthritis, lumbosacral
radiculopathy, and fibromyalgia. Several neurodegen-
erative disorders, such as Parkinson disease (PD) and
multiple system atrophy, usually occurring among eld-
erly patients can also be the cause of RLS11. Nonetheless,
the higher prevalence of RLS in patients with PD is
possibly attributable to the long-term antiparkinson-
ism therapy, rather than PD itself12.
Clinical and neurophysiologic examinations should
be performed to rule out potentially treatable illnesses
that may cause or exacerbate secondary RLS. These
examinations should be directed towards seeking evi-
dence of peripheral nerve or spinal dysfunction. Blood
tests are done primarily to screen for anemia, iron
storage dysfunction, diabetes, and renal insufficiency.
More than two-thirds of people who develop RLS for
the first time after 64 years of age have an underlying
cause such as iron deficiency13. Interestingly, iron defi-
ciency can be present in the absence of anemia. Thus,
iron status, as indicated by serum ferritin levels and
iron saturation, should be assessed, because patients
may benefit from iron supplementation when the
serum ferritin level is <50 ng/mL. There is some evi-
dence that oral iron supplementation is effective in
low–normal ferritin patients with RLS14.
Treatment of RLS
Not everybody with RLS requires pharmacologic therapy.
In a population-based survey with 1,312 participants
in Germany15, about 20% of RLS patients requested med-
ication to reduce their symptoms, corresponding to only
1.6% of the whole study population. Before starting
pharmacologic treatment, treatment of any medical
condition contributing to RLS is essential. Maintaining
good sleep hygiene practices, such as stable bedtimes
and rising times, a comfortable environment and
avoiding daytime napping, is helpful to some degree.
Regular exercise was also effective in improving RLS
symptoms in one randomized controlled trial16. A proof-
of-concept trial reported that cognitive behavioral group
therapy significantly improved RLS-related quality of
life and the mental health status of patients17. Addi-
tionally, current evidence suggests that compression
stockings improve symptoms and, therefore, quality of
life of some patients18. Certain stimulants or “aggra-
vating” drugs (e.g., caffeine, tobacco, alcohol, sedating
antihistamines, neuroleptics, tricyclic antidepressants,
selective serotonin reuptake inhibitors, and lithium)
should be avoided19. There is a strong association be-
tween RLS symptoms and Diagnostic and Statistical
Manual of Mental Disorders (fourth edition) (DSM-IV)
major depressive disorder. Up to four of the nine symp-
toms listed in the DSM-IV diagnostic criteria for major
depressive disorder can be attributed to sleep impair-
ment associated with RLS, including insomnia, loss of
energy, diminished concentration and psychomotor
retardation20. To date, no recommendations exist for
the treatment of depressive disorders in RLS. The
problem was most pronounced with mirtazapine pro-
voking or deteriorating RLS in 28% of patients. By con-
trast, no case occurred during use of reboxetine21.
Bupropion was a possible treatment option for RLS in
patients with depression. Case reports showed that a
low dose of bupropion rapidly and completely amelio-
rated RLS symptoms within a few days of the initiation
of treatment22.
Although a variety of treatments are proposed for
RLS, four identified classes of medications are com-
monly in use: (1) dopamine agonists and levodopa; (2)
gabapentin and similar anticonvulsants; (3) opioids;
and (4) benzodiazepines. An algorithm of the manage-
ment of RLS product by the Medical Advisory Board of
the RLS Foundation, divides RLS into three categories
according to symptom severity: (1) intermittent RLS,
(2) daily RLS, and (3) refractory RLS (Figure). According
to evidence-based medicine criteria, dopamine ago-
nists are currently considered to be first-line treatment
for moderate to severe RLS24. Levodopa was the first
drug approved by a government regulatory agency for
treatment of RLS, but only in Germany, Switzerland,
Austria, Croatia, Poland, and Brazil. It is rapidly effec-
tive with few adverse effects, except for the major prob-
lem of augmentation phenomenon. Its short-acting
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property seems to be an appropriate substance for
treating mild and intermittent RLS. Currently, only
ropinirole and pramipexole are approved by the US
Food and Drug Administration for treatment of mod-
erate to severe primary RLS. The two drugs can be dis-
tinguished by primarily hepatic (ropinirole) versus renal
(pramipexole) excretion and by half-life (6 hours for
ropinirole, 8–12 hours for pramipexole). Thus, ropini-
role should be the first drug considered in uremic
patients with RLS. An indirect meta-analysis confirmed
the superior efficacy and tolerability of pramipexole
over ropinirole. These findings should be further con-
firmed in a clinical trial comparing the two drugs25.
The new dopamine agonist rotigotine, a transdermal
patch, provides continuous drug delivery, benefits
patients with daytime symptoms, and is generally well
tolerated by the majority of RLS patients. Application
site reactions were the main treatment complication.
The manufacturer has filed for an indication for RLS
therapy in Europe. Other dopamine agonists, such as
pergolide and cabergoline, have been studied in reason-
ably large, double-blind, controlled studies. They cause
cardiac valvular fibrosis and do not appear to have
any particular advantage over other dopaminergic
agents. Thus, they are not considered primary treat-
ments for RLS. If one dopamine agonist causes side
effects or does not relieve symptoms, physicians should
consider prescribing another drug instead. The choice
of drug depends on the patient’s history, severity of
the RLS, and the preference of both the patient and
the physician for the drug.
Gabapentin and low-dose opioids are useful second-
line drugs that can be used alone or in combination
with dopaminergic agonists for dosage sparing. It seems
that derangement of opioid binding and dopamine–
opiate interactions play a role in the pathophysiology
of RLS. It provides a rationale for use of opioids in RLS
treatment26. Currently, only one double-blind random-
ized crossover trial with oxycodone (mean dosage,
15.9 mg) reduced sensory symptoms and motor rest-
lessness at night and during daytime27. In controlled
studies with gabapentin or its prodrug, RLS significantly
improved compared with placebo23,28. It is probably also
effective in secondary RLS and is especially helpful in
treating RLS with painful symptoms or associated neu-
ropathy. The gabapentin dosage should be reduced to
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Nonpharmacologic
management
Pharmacologic
management
Secondary RLS
Treatment of
primary disease
Idiopathic RLS
Intermittent RLS
Levodopa
Benzodiazepines
Dopamine
agonists
Low-potency
opioids
Daily RLS
Gabapentin
Dopamine
agonists
Low-potency
opioids
Change to gabapentin
Add benzodiazepine,
opioid or gabapentin
Change to a
high-potency opioid
Change to another
dopamine agonist
Refractory RLS
Abstinence from caffeine,
nicotine and alcohol
Consider drugs that
may enhance RLS
Alerting activities Iron replacement
Figure. Algorithm for the management of restless legs syndrome (RLS). Modified from Silber et al.23 with permission.
200–300 mg per day among hemodialysis patients29.
Dialysis does not improve RLS in uremic patients, but
renal transplantation does30. In contrast to earlier rec-
ommendations, benzodiazepines are not considered
as a first choice treatment for RLS because of their lim-
ited efficacy and the development of tolerance. They
should only be used when dopaminergic and opioid
drugs are contraindicated. The benefits from these med-
ications may be limited to a decrease in the number of
arousals during sleep. They may have a major role to
play as an add-on therapy to improve sleep.
Refractory RLS is defined as daily RLS treated with a
dopamine agonist, with one or more of the following
outcomes23: (1) an inadequate initial response despite
adequate doses; (2) a response that has become inade-
quate with time, despite increasing doses; (3) intolera-
ble adverse effects; and (4) an augmentation that is not
controllable with additional earlier doses of the drug.
There is no set formula for refractory RLS therapy.
Referral to a specialist for RLS management should be
considered, and each patient should have an individu-
alized treatment plan based on their needs and drug
tolerance. It is useful to perform a full sleep study for
these patients to ensure that there is no other sleep
disorder present. Sleep apnea often coexists with RLS,
and its symptoms may be masked by RLS. The treat-
ment of sleep apnea, if present, may alleviate RLS
symptoms. Changing or adding a treatment to a differ-
ent dopamine agonist or to gabapentin may also be
helpful in such cases. In general terms, augmentation
is an overall increase in symptom severity as a result of
long-term dopaminergic treatment. It describes an
increase in the severity of RLS, such as a time shift of
the start of symptoms to earlier in the day, a shorter
latency to RLS symptoms at rest, and/or a spreading of
symptoms to other body parts31. Although augmentation
initially was thought to be an exclusive problem of
levodopa treatment, it develops with other dopami-
nergic or opioid drugs as well. Augmentation needs to
be differentiated from rebound in clinical practice,
particularly because the increase in daily dose typi-
cally carried out to treat rebound will inevitably lead
to a worsening of augmentation. To avoid augmen-
tation, we recommend starting treatment with low
dosages and to keep them low during the course of
treatment. People who develop augmentation under
levodopa treatment should be treated with lower and
split dosages in mild cases. In more severe cases, levo-
dopa has to be stopped and treatment switched to a
dopamine agonist. If augmentation occurs again with
dopamine agonist treatment, treatment should be
split into low dosages or changed to an opiate.
Treatment of RLS in the Elderly
To date, no study has specifically investigated RLS treat-
ment for the elderly. Pooled data revealed that ropini-
role provided effective relief of symptoms, regardless
of age, at RLS symptom onset32. Older patients are prone
to insomnia, daytime somnolence, orthostatic hypoten-
sion, nausea and dizziness with dopaminergic agents,
and side effects that may preclude or limit their use.
As side effects of all dopamine agonists are dose-related,
the best strategy is to start medication cautiously and
at the lowest recommended dosage. In RLS patients
with dementia who wander, an empirical trial of a low-
dose dopaminergic agonist should be used. The cli-
nician must, however, bear in mind that because of
possible dopamine-induced psychosis in a potentially
vulnerable patient population, rapid dose escalation
of such medications is ill advised. Opioids seem to
have long-term efficacy in the treatment of RLS but
may result in a higher risk of dependency and worsen-
ing of sleep apnea33. These drugs are less suited to ge-
riatric patients because of their propensity to cause
confusion, sedation, and constipation. Clinical or poly-
somnographic monitoring for the development of sleep
apnea is recommended in patients on long-term opioid
therapy. It should be kept in mind that for the demen-
tia population, atypical antipsychotics (e.g., olanza-
pine, quetiapine and risperidone) that exert partial
dopaminergic blocking effects may aggravate RLS.
Conclusion
A detailed history of the patient, with corroboration
from the caregivers, if necessary, is important in RLS
diagnosis. RLS should be considered in the differential
diagnosis of any older patient with sleep disturbances
and/or paresthesia of the limbs. An initial approach
should examine potential exacerbating medications
already in use before adding new ones. Nonpharmaco-
logic management should be considered in all RLS
patients whether they have mild or severe symptoms.
Treatment with dopaminergic drugs, opioids, anticon-
vulsants or hypnotics is usually well tolerated by elderly
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patients. However, interaction with other medications
and the possibility of severe sedation due to slower me-
tabolism among the elderly should be considered. The
clinically relevant problem with dopaminergic drugs
in treating RLS is the development of augmentation,
which usually occurs after an initial improvement and
requires a switch of medication.
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